Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-20-003882
Filing Date
2020-03-20
Accepted
2020-03-20 17:17:02
Documents
6
Period of Report
2020-05-05
Effectiveness Date
2020-03-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2020proxystatement.htm DEF 14A 1006708
2 ajbackgroundpicture.jpg GRAPHIC 10605
3 cumberlandlogoa02a01.jpg GRAPHIC 12534
4 cumberlandpharmalogoa01.jpg GRAPHIC 37721
5 untitleda01a01.jpg GRAPHIC 9167
6 xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-20-003882.txt   1108136
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 20732859
SIC: 2834 Pharmaceutical Preparations